薬理学的標的としての脂質タンパク質:前提,希望,見通し
Antonio Greco1, Simone Finocchiaro1, Marco Spagnolo1
1Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico "G. Rodolico-San Marco," University of Catania, Italy.
Circulation
|February 10, 2025
まとめ
脂質タンパク質 (a) [Lp(a) ]は,動脈硬化性心血管疾患の強力な遺伝的リスク因子である. 高いLp (a) レベルを有する個人を特定することで,予防戦略を導き,心血管疾患を減らすことができます.
科学分野:
- 心臓病科
- 遺伝学
- 生物化学
背景:
- 動脈硬化性心血管疾患 (ASCVD) は,世界的な健康問題です.
- 脂質タンパク質 (a) [Lp(a) ]は,アテロゲン性においてLDLコレステロールを上回る独立したASCVDリスク因子として認識されています.
- Lp (a) は,酸化フォスホリピドの蓄積と線維分解の干渉を含む,炎症性および血栓性メカニズムを通じてASCVDに寄与する.
研究 の 目的:
- 心血管疾患の危険因子としてのLp (a) の重要性を強調する.
- Lp (a) 誘発性動脈栓塞の背後にあるメカニズムについて議論する.
- Lp (a) の減少のための現在および新興の治療戦略をレビューする.
主な方法:
- 遺伝子研究 (メンデルのランダム化) と臨床試験分析のレビュー
- Lp (a) のアテロゲン経路 (例えば,血管壁への侵入,受容体相互作用) の検査
- 新しいLp (a) 低下療法に関する進行中の臨床試験の概要
主要な成果:
- 遺伝学的な研究では,Lp (a) の上昇と心血管疾患との因果関係が確認されています.
- Lp (a) は,等分量ベースでLDLよりも著しく高いアテロゲニシティーを表しています.
- Lp (a) を標的とする複数の薬剤のクラスは臨床開発中であり,治療効果が有望である.
結論:
- 一回限りのLp (a) 測定は,遺伝的根拠によりリスクのある個人を特定することができます.
- Lp (a) の治療的減少は,心血管疾患のリスクを軽減すると予想されます.
- 増加したLp (a) 検査と標的治療は,心血管疾患の予防のための有望な集団レベル戦略を提供します.
関連する概念動画
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
517
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
517
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
145
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
145
01:18Factors Affecting Protein-Drug Binding: Drug-Related Factors
71
Drug binding to proteins is a complex phenomenon influenced by various drug-related factors, each playing a significant role in the interaction between drugs and proteins within the body.
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
71
01:20Factors Affecting Protein-Drug Binding: Protein-Related Factors
112
Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
112
01:07Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
26
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
26
01:25Blood Studies for Cardiovascular System III: Serum Lipid Profile
118
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
118